Minerva Neurosciences | NERV - Sales Revenues


Minerva Neurosciences reported $0 in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Adma Biologics USD 139.16M 4.94M Dec/2025
ALKERMES USD 384.5M 9.7M Dec/2025
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cipla INR 75.18B 710M Dec/2025
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 67.33M 65.44M Dec/2025
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Grifols EUR 2.34B 33.3M Mar/2026
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
J&J USD 24.1B 500M Mar/2026
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024